https://orcid.org/0000-0003-0798-3444
References
- Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727–13. doi: 10.1056/NEJMoa2001017
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5
- Organization WH. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update, 2020. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/. 2020
- Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 Feb;21(2):181–192.
- Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 Aug 15;396(10249):479–488. doi: 10.1016/S0140-6736(20)31605-6
- Polack F, Thomas S, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577
- Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020 Jul 3;369(6499):77–81. doi: 10.1126/science.abc1932
- Benton DJ, Wrobel AG, Xu P, et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature. 2020 Dec;588(7837):327–330.
- Royce TJ, Zhao Y, Ryals CA. Improving diversity in clinical trials by using real-world data to define eligibility criteria. JAMA Oncol. 2023 Apr 1;9(4):455–456. doi: 10.1001/jamaoncol.2022.7170
- Brouillette M. The FDA brings real-world data head to head with clinical trials. Nature Med. 2020 Mar;26(3):302–303. doi: 10.1038/s41591-020-0772-0
- Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020 Sep;38(9):1073–1078.
- Cui GY, Rao BC, Zeng ZH, et al. Characterization of oral and gut microbiome and plasma metabolomics in COVID-19 patients after 1-year follow-up. Mil Med Res. 2022 Jun 17;9(1):32. doi: 10.1186/s40779-022-00387-y
- Qian C, Zhou M, Cheng F, et al. Development and multicenter performance evaluation of fully automated SARS-CoV-2 IgM and IgG immunoassays. Clin Chem Lab Med. 2020 Aug 27;58(9):1601–1607. doi: 10.1515/cclm-2020-0548
- Tanriover MD, Doganay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021 Jul 17;398(10296):213–222. doi: 10.1016/S0140-6736(21)01429-X
- Fadlyana E, Rusmil K, Tarigan R, et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: an interim analysis in Indonesia. Vaccine. 2021 Oct 22;39(44):6520–6528. doi: 10.1016/j.vaccine.2021.09.052
- Jara A, Undurraga EA, Gonzalez C, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021 Sep 2;385(10):875–884. doi: 10.1056/NEJMoa2107715
- Guzel EC, Yildiz T, Buyukkiyici O, et al. Safety and adverse effects of inactive SARS-Cov-2 vaccine (CoronaVac) in health care professionals. J Pak Med Assoc. 2022 Sep;72(9):1792–1796.
- Zhang MX, Zhang TT, Shi GF, et al. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Rev Vaccines. 2021 Jul;20(7):891–898.
- Zhang J, Xing S, Liang D, et al. Differential antibody response to inactivated COVID-19 vaccines in healthy subjects. Front Cell Infect Microbiol. 2021;11:791660. doi: 10.3389/fcimb.2021.791660
- Caglayan D, Suner AF, Siyve N, et al. An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey. J Med Virol. 2022 May;94(5):2212–2221.
- Banga Ndzouboukou JL, Zhang YD, Lei Q, et al. Human IgM and IgG responses to an inactivated SARS-CoV-2 vaccine. Curr Med Sci. 2021 Dec;41(6):1081–1086.
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020 Dec 31;383(27):2603–2615. doi: 10.1056/NEJMoa2034577
- Halperin SA, Ye L, MacKinnon-Cameron D, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2022 Jan 15;399(10321):237–248. doi: 10.1016/S0140-6736(21)02753-7
- Cowling BJ, Wong IOL, Shiu EYC, et al. Strength and durability of antibody responses to BNT162b2 and CoronaVac. Vaccine. 2022 Jul 30;40(32):4312–4317. doi: 10.1016/j.vaccine.2022.05.033
- Guzel EC, Celikkol A, Erdal B, et al. Immunogenicity after CoronaVac vaccination. Rev Assoc Med Bras. 2021 Oct;67(10):1403–1408.
- Yildiz Y, Ozger HS, Senol E, et al. Evaluation of long-term antibody kinetics in healthcare workers vaccinated with inactivated COVID-19 Vero cell vaccine (CoronaVac), a propensity score-matched observational study. Int J Infect Dis. 2022 Sep;122:99–106.